News
Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...
The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.
Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
Synchrony Medical announced that it received FDA 510 (k) clearance for its LibAirty airway clearance system.
Frequent consumption of a common drug that acts on the nervous system and treats a range of ailments may lead to faster ...
The CAAT governance board recommends transitioning from the COPD Assessment Test to the CAAT and using it for patients with ...
The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.
Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...
Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...
Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results